Adarx Pharmaceuticals
- Market cap
- 1.77B
- P/E (TTM)i
- -20.15
- P/Bi
- -7.06
- EPSi
- -0.97
- Div yieldi
- 0.00%
- 52W posi
- 2%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
- Total institutional ownership rose 49.4 percentage points.
Institutional ownership
- Held by institutions
- 49.36% +49.36pp
- Institutions
- 5 +5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 7 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2026-10-02
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
19 filings tracked · 10 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| OrbiMed Advisors LLC | -- | 22.13% |
| Eli Lilly Investment Consulting (Shanghai) Co., Ltd. | -- | 10.58% |
| Li Zhen | -- | 5.23% |
| Rui Zhu | Chief Technology Officer | 2.24% |
| Mary Tagliaferri | Independent Director | -- |
| Ying Huang | Independent Director | -- |
| SR One Capital Management, LP | -- | -- |
| Robert Ackles | Chief Human Resources Officer | -- |
| A. MacLeod | Chief Scientific Officer | -- |
| Ryan Fisk | CFO & Chief Business Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-27 | OrbiMed Advisors LLC | -- | Private Acquisition | +950,000 | $17.00 |
| 2026-09-27 | OrbiMed Advisors LLC | -- | Derivative Exercise and Retained | +23,255,789 | -- |
| 2026-09-27 | Eli Lilly Investment Consulting (Shanghai) Co., Ltd. | -- | Derivative Exercise and Retained | +11,858,655 | -- |
| 2026-09-27 | SR One Capital Management, LP | -- | Private Acquisition | +1,600,000 | $17.00 |
| 2026-09-27 | SR One Capital Management, LP | -- | Derivative Exercise and Retained | +8,336,661 | -- |
| 2026-09-23 | Mary Tagliaferri | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | Ying Huang | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | Li Zhen | -- | Other Derivative Acquisition | +1,024,152 | $17.00 |
| 2026-09-23 | Li Zhen | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | Robert Ackles | Chief Human Resources Officer | Other Derivative Acquisition | +85,346 | $17.00 |
| 2026-09-23 | Robert Ackles | Chief Human Resources Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | A. MacLeod | Chief Scientific Officer | Other Derivative Acquisition | +170,692 | $17.00 |
| 2026-09-23 | A. MacLeod | Chief Scientific Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | Ryan Fisk | CFO & Chief Business Officer | Other Derivative Acquisition | +170,692 | $17.00 |
| 2026-09-23 | Ryan Fisk | CFO & Chief Business Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | Rui Zhu | Chief Technology Officer | Other Derivative Acquisition | +512,076 | $17.00 |
| 2026-09-23 | Rui Zhu | Chief Technology Officer | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:27:44 · For reference only, not investment advice and not tailored to your situation.